ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(4.08) by 54.41 percent. This is a 99.59 percent increase over losses of $(449.58) per share from the same period last year.